Tarsus officer plans $943K Rule 144 stock sale

Officer Elizabeth Yeu-Lin filed a Rule 144 notice to resell 10,773 Tarsus common shares, with recent family-account sales disclosed and aggregated.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) received a Rule 144 notice for a planned resale of common stock by company officer Elizabeth Yeu-Lin. The notice covers 10,773 shares of common stock, acquired in open market purchases on September 14, 2022 and August 15, 2023, with an aggregate market value of $942,635.00 as of the notice.

The filing states that Tarsus had 43,882,996 shares of common stock outstanding. It also lists sales during the past three months totaling 11,578 shares of common stock for approximately $897,989.86, including sales from the account of the officer’s spouse, which are aggregated under Rule 144.

Key Figures

Shares to be sold under Rule 144: 10,773 shares Aggregate market value of shares to be sold: $942,635.00 Shares outstanding: 43,882,996 shares +4 more

7 metrics

Shares to be sold under Rule 144 10,773 shares Proposed resale of Tarsus common stock by officer Elizabeth Yeu-Lin

Aggregate market value of shares to be sold $942,635.00 Value of 10,773 Tarsus common shares covered by the notice

Shares outstanding 43,882,996 shares Tarsus Pharmaceuticals common stock outstanding as stated in the notice

Shares sold in past 3 months by officer 9,988 shares 4,601 shares on September 1, 2026 and 5,387 shares on September 2, 2026

Shares sold in past 3 months by spouse 1,590 shares Sales from account of spouse Stephen H. Lin on September 2, 2026

Total shares sold in past 3 months 11,578 shares Combined sales by Elizabeth Yeu-Lin and spouse reported under Rule 144

Proceeds from past 3 months’ sales $897,989.86 Combined consideration for 11,578 shares sold in the past three months

Key Terms

Rule 144, Open Market Purchase, aggregate market value, attorney-in-fact

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Open Market Purchase financial

"Common | 08/15/2023 | Open Market Purchase | Issuer"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

aggregate market value financial

"Common | Fidelity Brokerage Services LLC ... | 10773 | 942635.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

attorney-in-fact regulatory

"as attorney-in-fact for Elizabeth Yeu-Lin."

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing disclose for Tarsus Pharmaceuticals (TARS)?

It discloses that officer Elizabeth Yeu-Lin filed a Rule 144 notice to sell 10,773 shares of Tarsus common stock, with an aggregate market value of $942,635.00, based on Tarsus having 43,882,996 shares of common stock outstanding.

How many TARS shares are covered by the new Rule 144 notice?

The notice covers 10,773 shares of Tarsus Pharmaceuticals common stock. These shares were acquired in open market purchases on September 14, 2022 (6,020 shares) and August 15, 2023 (4,753 shares), both for cash.

What recent TARS share sales by the officer and spouse are reported?

Over the past three months, the filing reports sales totaling 11,578 shares of Tarsus common stock for about $897,989.86: 4,601 shares on September 1, 2026 and 5,387 shares on September 2, 2026 by Elizabeth Yeu-Lin, and 1,590 shares on September 2, 2026 by spouse Stephen H. Lin.

What is the reported market value and share count context for TARS in this filing?

The Rule 144 notice states an aggregate market value of $942,635.00 for the 10,773 shares proposed for sale. It also reports that Tarsus Pharmaceuticals had 43,882,996 shares of common stock outstanding at the time referenced.

Why are the spouse’s TARS share sales included in this Form 144?

The remarks explain that sales in the past three months include those from the account of Stephen H. Lin, the spouse of officer Elizabeth Yeu-Lin. These are included because Rule 144 requires aggregation of certain related persons’ sales.

Who is acting for the selling security holder in the TARS Form 144?

The notice is signed by Joshua Schmitt as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Elizabeth Yeu-Lin, the officer on whose behalf the securities are to be sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:00 PM Accepted by SEC EDGAR 09/04/2026 - 03:59 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001842190
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tarsus Pharmaceuticals, Inc.
SEC File Number	001-39614
Address of Issuer	15440 LAGUNA CANYON ROAD IRVINE CALIFORNIA 92618
Phone	(949) 409-9820
Name of Person for Whose Account the Securities are To Be Sold	Lin Elizabeth Yeu
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	10773	942635.00	43882996	09/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2023	Open Market Purchase	Issuer			4753	08/15/2023	Cash
Common	09/14/2022	Open Market Purchase	Issuer			6020	09/14/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Elizabeth Yeu-Lin 17700 Laguna Canyon Road Floor 4 Irvine CA 92618	Common	09/01/2026	4601	339829.86
Elizabeth Yeu-Lin 17700 Laguna Canyon Road Floor 4 Irvine CA 92618	Common	09/02/2026	5387	430960.00
Stephen H. Lin 17700 Laguna Canyon Road Floor 4 Irvine CA 92618	Common	09/02/2026	1590	127200.00

144: Remarks and Signature

Remarks	Sales from the past 3 months include those from the account of Stephen H. Lin who is the spouse of Elizabeth Yeu-Lin, an officer of the company.
Date of Notice	09/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Elizabeth Yeu-Lin.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)